Light may replace needle for breast cancer diagnosis
NCT ID NCT06857669
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether special light-based scans (photoacoustic imaging and diffuse reflectance spectroscopy) can tell the difference between healthy, benign, and malignant breast tissue. Researchers will scan 90 women with known breast lumps and compare the scan results to standard tissue analysis. If the optical technique works, it could offer a faster, painless way to diagnose breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Diffuse reflectance spectroscopy and photoacoustic imaging
- What this could lead to
- If successful, this could lead to a non-invasive, radiation-free way to diagnose breast cancer, reducing the need for biopsies.
- What could go wrong
- This is an early-stage diagnostic study with only 90 participants. The technique may not be accurate enough to replace standard biopsy, and results may not apply to all breast types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2020
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * solitary malignant or benign biopsy verified tumour \> 1 cm * understands written and oral Swedish Exclusion Criteria: * previous breast surgery * has received neoadjuvant chemotherapy * skin burns in on the chest
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign breast tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Skane University Hospital
RECRUITINGMalmö, 20502, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?